For Those Who Prefer to Know

Radence was founded on a simple conviction: serious disease is too often discovered only after it has progressed. 

Disease rarely arrives without warning. Early biological signals can emerge years before diagnosis, when trajectories can still be redirected. We were built to find those signals before they become impossible to ignore.

Prevention Requires Continuity

Modern medicine is exceptionally capable. But it is not structured to track subtle biological change year after year against your own baseline. Without that baseline, small but meaningful shifts can be missed. Prevention depends on consistency. Radence was created to provide it.

The Principles That Guide
Everything We Do

Every diagnostic. Every finding. Every recommendation. Governed by the same standards.

Evidence Before Adoption

New diagnostics are incorporated only when they meet defined thresholds for clinical relevance and interpretability.

Interpretation Before Action

Advanced testing generates information. Multidisciplinary review determines significance.

Clinical Relevance Over Novelty

Meaningful signal takes precedence over emerging trend.

Coordination Over Fragmentation

Findings are integrated in partnership with each member’s existing physicians.

Continuity Over
Episodic Testing

Prevention requires sustained attention and disciplined follow-through.

Want to experience the best that medicine can be?

Request Membership Consultation

Access Breakthrough Healthcare Technologies Before They Break Through.

Radence was built within Raven, the healthcare incubator of RA Capital Management. RA Capital’s dedicated team of more than 50 MDs and PhDs continuously evaluates novel medicines, diagnostics, and clinical technologies.

That scientific rigor shapes the Radence standard of care. Each diagnostic is assessed for clinical validity, utility, and interpretability before it is included in a member’s protocol. We do not adopt tools because they are new. Only those which meet defined thresholds make the cut.

For members, that means earlier insight, fewer unknowns, and access to advanced prevention strategies years before they reach traditional healthcare, helping you intercept risk and preserve your healthy, functional years.
Inquire About Membership
Start Your Discovery

Precision and Purpose

With highly curated early detection testing — including proprietary protocols for genomics, serum biomarkers, imaging, and innovative scientific testing focused on cancer, neurodegenerative disease, cardiovascular disease, and metabolic disorders — we offer our members a new standard science-backed support.
Man reading newspaper casually with children sitting by pool

Why We Exist

Radence was built by people who spend their lives at the edge of medical science, evaluating new data, new therapies, and what’s possible.

When you see how early disease can be detected, and how much earlier it could be acted on, it becomes impossible to accept a system that waits.

We exist because that gap is real.

And because once you understand it, settling for standard care is no longer an option.

Leadership

Radence is led by a deliberately assembled team of clinicians, scientists, and operators with deep experience in precision medicine, biomedical research, member experience, and data-driven healthcare strategy. Each leader brings domain expertise in areas central to Radence’s mission: early disease detection, clinical interpretation, longitudinal risk management, and responsible integration of emerging diagnostics.
David Medvedeff - Radence CEO
David Medvedeff, PharmD, MBA

CEO

Dr. David Medvedeff is the CEO of Radence and a seasoned leader in healthcare innovation. He co-founded and served as CEO of Aspen RxHealth, which was acquired by MedImpact. David previously led several successful companies, including Gold Standard, Avatar International, and VUCA Health. Each was acquired by major industry players. Known for driving growth and delivering impact, David has received numerous honors, including the National Prescott Award and the Next Generation Pharmacist Technology Innovator Award. He is also the only two-time recipient of the Pinnacle Award from the American Pharmacists Association Foundation, recognizing lasting contributions to the healthcare field.

Dr. David Medvedeff is the CEO of Radence and a seasoned leader in healthcare innovation. He co-founded and served as CEO of Aspen RxHealth, which was acquired by MedImpact. David previously led several successful companies, including Gold Standard, Avatar International, and VUCA Health. Each was acquired by major industry players. Known for driving growth and delivering impact, David has received numerous honors, including the National Prescott Award and the Next Generation Pharmacist Technology Innovator Award. He is also the only two-time recipient of the Pinnacle Award from the American Pharmacists Association Foundation, recognizing lasting contributions to the healthcare field.

Julie Chen, MD

Chief Medical Officer

Dr. Julie Chen is the Chief Medical Officer at Radence. She previously served as Chief Medical Officer at companies such as Human Longevity and Vitagene. Her research, at the FDA, NIH, National Cancer Institute, USC, and Mount Sinai, has shaped scientific advancement in precision medicine. As a fellowship-trained integrative internal medicine physician, she developed numerous corporate wellness programs in Silicon Valley focusing on whole-systems approach to healthcare. Dr. Chen is a frequent medical expert on major media outlets, including ABC, NBC, FOX, and MSN, and she has been featured in national magazines and podcasts. In 2023, she was named one of the Top 25 Women Leaders in Biotechnology by Healthcare Technology Report for her leadership in health tech development. Dr. Chen is a member of the Buck Institute's President's Circle, dedicated to advancing research in aging and longevity.

Dr. Julie Chen is the Chief Medical Officer at Radence. She previously served as Chief Medical Officer at companies such as Human Longevity and Vitagene. Her research, at the FDA, NIH, National Cancer Institute, USC, and Mount Sinai, has shaped scientific advancement in precision medicine. As a fellowship-trained integrative internal medicine physician, she developed numerous corporate wellness programs in Silicon Valley focusing on whole-systems approach to healthcare. Dr. Chen is a frequent medical expert on major media outlets, including ABC, NBC, FOX, and MSN, and she has been featured in national magazines and podcasts. In 2023, she was named one of the Top 25 Women Leaders in Biotechnology by Healthcare Technology Report for her leadership in health tech development. Dr. Chen is a member of the Buck Institute's President's Circle, dedicated to advancing research in aging and longevity.

Wuhong Li - CTO of Radence
Wuhong Li, MS

Chief Technology Officer

Wuhong Li, Chief Technology Officer at Radence, is an award-winning technology leader and healthcare innovator. With a proven track record in patient care, clinical decision support, health informatics, and data intelligence, he has co-founded and led multiple PE/VC-backed digital health companies. Wuhong has successfully built and scaled teams across software engineering, cloud infrastructure, IT operations, and security. His innovative contributions have earned recognition from Microsoft, Computerworld, HIMSS, and Great Entrepreneurs, which named him one of the Top 25 Entrepreneurs of Tampa for 2024.

Wuhong Li, Chief Technology Officer at Radence, is an award-winning technology leader and healthcare innovator. With a proven track record in patient care, clinical decision support, health informatics, and data intelligence, he has co-founded and led multiple PE/VC-backed digital health companies. Wuhong has successfully built and scaled teams across software engineering, cloud infrastructure, IT operations, and security. His innovative contributions have earned recognition from Microsoft, Computerworld, HIMSS, and Great Entrepreneurs, which named him one of the Top 25 Entrepreneurs of Tampa for 2024.

Sarah Pesce - Radence COO
Sarah Pesce, ANP, MSCDL

Chief Operating Officer

Sarah Pesce is the Chief Operating Officer at Radence. She previously served as COO of Thorne Lab, a division of Thorne HealthTech, where she led the development of a clinical platform offering a comprehensive, 360-degree view of individual health. Prior to Thorne, Sarah was COO of Lab100 at Mount Sinai Medical Center, where she shaped clinical operational strategies for advanced digital screening assessments. She also served as Senior Director of Business Development and Clinical Operations for Mount Sinai’s Executive Health Program and worked as Nurse Practitioner for Dr. Valentine Fuster, managing complex cardiology patients and launching impactful ambulatory programs.

Sarah Pesce is the Chief Operating Officer at Radence. She previously served as COO of Thorne Lab, a division of Thorne HealthTech, where she led the development of a clinical platform offering a comprehensive, 360-degree view of individual health. Prior to Thorne, Sarah was COO of Lab100 at Mount Sinai Medical Center, where she shaped clinical operational strategies for advanced digital screening assessments. She also served as Senior Director of Business Development and Clinical Operations for Mount Sinai’s Executive Health Program and worked as Nurse Practitioner for Dr. Valentine Fuster, managing complex cardiology patients and launching impactful ambulatory programs.

Page Ikeda

Chief Product Officer

Page Ikeda is the Chief Product Officer at Radence and a product and design leader with more than two decades of experience at the intersection of technology, user experience, and healthcare strategy. She previously served as Chief Product Officer at Aspen RxHealth, where she drove product strategy and built scalable, user-centric solutions strengthening pharmacist-patient engagement and outcomes. Prior roles include product and design leadership at HatchWorks, Philips — where she advanced population health innovation — and The Coca-Cola Company, where she led global digital platform initiatives supporting hundreds of brands. Known for translating complex challenges into intuitive, user-centered solutions, Page combines strategic leadership with hands-on execution to deliver high-impact digital products aligned with business goals.

Page Ikeda is the Chief Product Officer at Radence and a product and design leader with more than two decades of experience at the intersection of technology, user experience, and healthcare strategy. She previously served as Chief Product Officer at Aspen RxHealth, where she drove product strategy and built scalable, user-centric solutions strengthening pharmacist-patient engagement and outcomes. Prior roles include product and design leadership at HatchWorks, Philips — where she advanced population health innovation — and The Coca-Cola Company, where she led global digital platform initiatives supporting hundreds of brands. Known for translating complex challenges into intuitive, user-centered solutions, Page combines strategic leadership with hands-on execution to deliver high-impact digital products aligned with business goals.

Clinical Advisory Board

Professional woman in business attire, representing smart health decisions and healthcare technology.
Fanny Elahi, MD, DPhil

Neurologist

Dr. Fanny Elahi is a physician-scientist and Associate Professor of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai in New York City. She directs fluid biomarker research at the Barbara and Maurice Deane Center for Wellness and Cognitive Health and co-directs the Biomarkers and Genomics Core of the Mount Sinai Alzheimer’s Disease Research Center, where she leads efforts to develop novel blood biomarkers for neurodegenerative diseases. Her research program is at the forefront of breaking down disciplinary silos to advance therapeutic discovery for dementia, with a particular focus on genetic diseases such as CADASIL. By integrating molecular techniques, clinical data, and advanced analytics, Dr. Elahi and her team are uncovering the mechanistic links between blood vessel disease and neurodegeneration. A major emphasis is on the development of blood biomarkers and their integration with in vitro and in vivo disease models to identify new drug targets. She is passionate about translating laboratory findings into clinical applications, and drug discovery for dementia-causing diseases. Dr. Elahi earned a BS in Comparative Literature and Society from Columbia University, a DPhil in Neurogenetics from the University of Oxford, and an MD from the Icahn School of Medicine at Mount Sinai.

Dr. Fanny Elahi is a physician-scientist and Associate Professor of Neurology, Neuroscience, and Pathology at the Icahn School of Medicine at Mount Sinai in New York City. She directs fluid biomarker research at the Barbara and Maurice Deane Center for Wellness and Cognitive Health and co-directs the Biomarkers and Genomics Core of the Mount Sinai Alzheimer’s Disease Research Center, where she leads efforts to develop novel blood biomarkers for neurodegenerative diseases. Her research program is at the forefront of breaking down disciplinary silos to advance therapeutic discovery for dementia, with a particular focus on genetic diseases such as CADASIL. By integrating molecular techniques, clinical data, and advanced analytics, Dr. Elahi and her team are uncovering the mechanistic links between blood vessel disease and neurodegeneration. A major emphasis is on the development of blood biomarkers and their integration with in vitro and in vivo disease models to identify new drug targets. She is passionate about translating laboratory findings into clinical applications, and drug discovery for dementia-causing diseases. Dr. Elahi earned a BS in Comparative Literature and Society from Columbia University, a DPhil in Neurogenetics from the University of Oxford, and an MD from the Icahn School of Medicine at Mount Sinai.

Bald man smiling in blue shirt, promoting smart health decisions and healthcare innovation.
Zahi A. Fayad, PhD

Biomedical Engineer

Dr. Zahi A. Fayad is the Lucy G. Moses Professor of Medical Imaging and Bioengineering and founding director of the BioMedical Engineering and Imaging Institute at Mount Sinai. A finalist in the XPRIZE Healthspan competition, his research brings together AI, imaging, and nanomedicine to advance precision medicine, with a focus on cardiovascular and immune-related diseases. He pioneered MRI vessel-wall imaging (CARADS), advanced PET imaging of vascular inflammation, and uncovered links between brain activity, inflammation, and cardiovascular risk. His work on HDL-based nanoparticles is moving toward clinical translation in cancer, autoimmune disease, and transplant rejection. Dr. Fayad also directs the Mount Sinai DigiTwin Project, an AI-driven platform for real-time, personalized health optimization. Dr. Fayad had his engineering trainings at Bradley University (BS, Electrical Engineering '89), the Johns Hopkins University (MS, Biomedical Engineering '91), and at the University of Pennsylvania (PhD Bioengineering '96). From 1996 to 1997 he was junior faculty in the Department of Radiology at the University of Pennsylvania. In 1997 he joined the faculty at the Mount Sinai School of Medicine as Assistant Professor in Radiology and Medicine (Cardiology).

Dr. Zahi A. Fayad is the Lucy G. Moses Professor of Medical Imaging and Bioengineering and founding director of the BioMedical Engineering and Imaging Institute at Mount Sinai. A finalist in the XPRIZE Healthspan competition, his research brings together AI, imaging, and nanomedicine to advance precision medicine, with a focus on cardiovascular and immune-related diseases. He pioneered MRI vessel-wall imaging (CARADS), advanced PET imaging of vascular inflammation, and uncovered links between brain activity, inflammation, and cardiovascular risk. His work on HDL-based nanoparticles is moving toward clinical translation in cancer, autoimmune disease, and transplant rejection. Dr. Fayad also directs the Mount Sinai DigiTwin Project, an AI-driven platform for real-time, personalized health optimization. Dr. Fayad had his engineering trainings at Bradley University (BS, Electrical Engineering '89), the Johns Hopkins University (MS, Biomedical Engineering '91), and at the University of Pennsylvania (PhD Bioengineering '96). From 1996 to 1997 he was junior faculty in the Department of Radiology at the University of Pennsylvania. In 1997 he joined the faculty at the Mount Sinai School of Medicine as Assistant Professor in Radiology and Medicine (Cardiology).

Friendly healthcare professional promoting smart health decisions, patient-centered care.
Nicholas A. Marston, MD

Cardiologist

Dr. Nicholas Marston is a Preventive Cardiologist at Brigham and Women's Hospital and Harvard Medical School, an Investigator and clinical trialist at the TIMI Study Group, and an NIH-funded researcher in genomic medicine. He holds leadership roles including Principal Investigator and National Lead Investigator in several lipid-lowering clinical trials testing genetically validated targets such as PCSK9, Lp(a), ApoC-III, ANGPTL3, and ANGPTL4. Clinically, Dr. Marston attends on the inpatient cardiology service and in the Cardiovascular Genetics Center and Preventive Cardiology Clinic, where he cares for patients with Familial Hypercholesterolemia, severe hypertriglyceridemia, elevated Lp(a), and premature coronary artery disease.

Dr. Nicholas Marston is a Preventive Cardiologist at Brigham and Women's Hospital and Harvard Medical School, an Investigator and clinical trialist at the TIMI Study Group, and an NIH-funded researcher in genomic medicine. He holds leadership roles including Principal Investigator and National Lead Investigator in several lipid-lowering clinical trials testing genetically validated targets such as PCSK9, Lp(a), ApoC-III, ANGPTL3, and ANGPTL4. Clinically, Dr. Marston attends on the inpatient cardiology service and in the Cardiovascular Genetics Center and Preventive Cardiology Clinic, where he cares for patients with Familial Hypercholesterolemia, severe hypertriglyceridemia, elevated Lp(a), and premature coronary artery disease.

Friendly male doctor smiling, healthcare professional in white coat for smart health decisions.
Christopher Mason, PhD

Geneticist

Dr. Christopher Mason is a WorldQuant Professor of Genomics and Computational Biomedicine at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction. He also holds affiliate appointments at the Tri-I Program on Computational Biology and Medicine (Cornell, Memorial Sloan Kettering Cancer Center and Rockefeller University), Harvard Medical School, and Yale Law School. His lab develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and physiology. The lab creates and deploys novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. Dr. Mason’s lab also works closely with NIST/FDA to build international standards for these methods (SEQC2, IMMSA, and Epigenomics QC groups), to ensure clinical-quality genome measurements and editing. His lab also works with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which help establish the molecular foundations and genetic defenses for enabling long-term human spaceflight. Dr. Mason has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, and he was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y.

Dr. Christopher Mason is a WorldQuant Professor of Genomics and Computational Biomedicine at Weill Cornell Medicine and the Director of the WorldQuant Initiative for Quantitative Prediction. He also holds affiliate appointments at the Tri-I Program on Computational Biology and Medicine (Cornell, Memorial Sloan Kettering Cancer Center and Rockefeller University), Harvard Medical School, and Yale Law School. His lab develops and deploys new biochemical and computational methods in functional genomics to elucidate the genetic basis of human disease and physiology. The lab creates and deploys novel techniques in next-generation sequencing and algorithms for: tumor evolution, genome evolution, DNA and RNA modifications, and genome/epigenome engineering. Dr. Mason’s lab also works closely with NIST/FDA to build international standards for these methods (SEQC2, IMMSA, and Epigenomics QC groups), to ensure clinical-quality genome measurements and editing. His lab also works with NASA to build integrated molecular portraits of genomes, epigenomes, transcriptomes, and metagenomes for astronauts, which help establish the molecular foundations and genetic defenses for enabling long-term human spaceflight. Dr. Mason has won the NIH's Transformative R01 Award, the NASA Group Achievement Award, and he was named as one of the "Brilliant Ten" Scientists by Popular Science, featured as a TEDMED speaker, and called "The Genius of Genetics" by 92Y.

Stylish man wearing red glasses, smiling confidently, representing smart health decisions and digital health solutions.
Jacob Oppenheim, PhD

Biomathematician, Bioinformatic, and Computational Biologist

Jacob Oppenheim is a Venture Partner at Raven, RA Capital Management's healthcare incubator. Prior to joining Raven, Dr. Oppenheim was an Entrepreneur-in-Residence at Digitalis Ventures and co-founded Fresnel, a ‘Bloomberg for Biology’ platform. He previously served as Vice President of Data Science and Engineering at EQRx, where he led the development of data strategy and implementation of scalable data infrastructure. Dr. Oppenheim also held leadership roles at Indigo, including Senior Director of Data Science, where he developed machine learning systems for agriculture applications. He holds extensive experience in building and scaling high-performing cross-functional teams in data science, engineering, and product development, with a focus on applying AI/ML to biological problems. Dr. Oppenheim has presented at top conferences and is named on multiple patent applications in the field. He holds a PhD in Biological Physics from Rockefeller University and an AB in Physics from Princeton University.

Jacob Oppenheim is a Venture Partner at Raven, RA Capital Management's healthcare incubator. Prior to joining Raven, Dr. Oppenheim was an Entrepreneur-in-Residence at Digitalis Ventures and co-founded Fresnel, a ‘Bloomberg for Biology’ platform. He previously served as Vice President of Data Science and Engineering at EQRx, where he led the development of data strategy and implementation of scalable data infrastructure. Dr. Oppenheim also held leadership roles at Indigo, including Senior Director of Data Science, where he developed machine learning systems for agriculture applications. He holds extensive experience in building and scaling high-performing cross-functional teams in data science, engineering, and product development, with a focus on applying AI/ML to biological problems. Dr. Oppenheim has presented at top conferences and is named on multiple patent applications in the field. He holds a PhD in Biological Physics from Rockefeller University and an AB in Physics from Princeton University.

The Greatest Advantage in Health is Not Access. It is Foresight.

Some people wait for answers. Others choose to understand what’s ahead.
Membership begins with a conversation.

Inquire About Membership
Schedule a Membership Consultation